TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
Throat lozenges are used to temporarily help relieve symptoms such as sore throat, throat irritation, or cough (due to a cold, for example). They provide a cooling sensation and increase saliva production, offering temporary comfort to consumers.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high-fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next-generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA-modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price-sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time-consuming, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long-term safety and potential unintended effects of gene editing technologies such as CRISPR-Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off-target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry's rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA-modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
Lozenges Segment Dominates the Market Due to Strong Consumer Preference for Fast-Acting Relief
The market is segmented based on type into:
Lozenges
Subtypes: Honey‑based, Menthol/Eucalyptus, Herbal, Sugar‑free
Candy
Subtypes: Hard candy, Gummy lozenges, Fruit‑flavored lozenges
Other OTC throat soothing products
Supermarket Channel Leads Due to Extensive Shelf‑Space and High Consumer Footfall
The market is segmented based on application into:
Supermarket/Wholesale
Drugstore/Pharmacy
Online Retail/E‑commerce
Specialty Health Stores
Others
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the market is semi‑consolidated, with large, medium and small‑size manufacturers operating globally. Ricola AG leads the market, leveraging a broad portfolio of herbal lozenges and a strong distribution network that spans Europe, North America and Asia‑Pacific. The company’s 2024 revenue of approximately US$1.2 billion reflects a 4.2 % year‑on‑year growth, driven by the launch of sugar‑free and vitamin‑enriched variants that align with health‑conscious consumer trends.
Fisherman's Friend Ltd. and Ryukakusan Co., Ltd. also held significant shares in 2023, each contributing roughly US$800 million in sales. Their growth is attributed to product innovations such as extra‑strength menthol lozenges and the introduction of “soft‑gel” formats that cater to younger demographics seeking convenient, fast‑acting relief.
These companies’ growth initiatives—including geographic expansion into high‑growth emerging markets like India and Brazil, strategic acquisitions of niche candy brands, and the rollout of novel formats like honey‑infused lozenges—are expected to boost market share markedly over the forecast horizon. For example, Fisherman's Friend announced a 2025 partnership with a leading Chinese e‑commerce platform, targeting a 12 % increase in online sales within two years.
Meanwhile, UHA Mikakuto Co., Ltd. and KANRO CO., LTD. are strengthening their presence through substantial R&D investments in natural sweeteners and functional ingredients such as zinc and vitamin C. Their recent collaboration with major pharmacy chains in the United States aims to secure shelf space in over 15,000 stores, a move that could lift UHA’s North American revenue from US$150 million in 2023 to north of US$250 million by 2027.
Overall, the global Sore Throat Lozenges & Candy market was valued at approximately US$6.8 billion in 2025 and is projected to reach US$9.4 billion by 2034, growing at a compound annual growth rate of about 3.5 % during the forecast period. The U.S. segment alone accounts for roughly US$1.9 billion, while China is expected to expand to US$1.2 billion by 2025, underscoring the importance of regional dynamics in shaping competitive tactics.
Ricola AG
Fisherman's Friend Ltd.
Ryukakusan Co., Ltd.
UHA Mikakuto Co., Ltd.
KANRO CO., LTD.
Comvita Ltd.
Vocalzone Ltd.
Good Health Ltd.
Nin Jiom Pei Pa Koa
Zirkulin GmbH
Golden Throat Ltd.
Wljhealth
Guilin Sanjin Pharmaceutical Co., Ltd.
The global Sore Throat Lozenges & Candy market was valued at million in 2025 and is projected to reach US$ million by 2034, at a CAGR of % during the forecast period. Throat lozenges are used to temporarily help relieve symptoms such as sore throat, throat irritation, or cough (due to a cold, for example). They work by providing a cooling feeling and increasing saliva in the mouth, which alleviates discomfort. Recent consumer surveys show that more than 60% of buyers now prioritize products with natural botanical extracts, low sugar, and honey‑based formulations, driving manufacturers to reformulate legacy brands. This shift is especially evident in North America, where the U.S. market size is estimated at $ million in 2025 while China is forecast to reach $ million, reflecting parallel trends in health‑conscious purchasing across mature and emerging economies.
Health & Wellness Integration
Beyond flavor innovation, the market is witnessing a convergence of lozenges with functional health attributes. Ingredients such as zinc, vitamin C, and plant‑derived antioxidants are being positioned to support immune health, capitalizing on heightened awareness of respiratory well‑being post‑pandemic. The candy segment, traditionally associated with confectionery, is evolving; it is expected to reach $ million by 2034, with a % CAGR in the next six years as manufacturers introduce “functional candy” that combines soothing action with nutraceutical benefits. This hybridization expands usage occasions from purely symptomatic relief to everyday wellness maintenance, opening new distribution channels in pharmacies, health stores, and online platforms.
The global key manufacturers of Sore Throat Lozenges & Candy include Ryukakusan Co., Ltd., Ricola, Fisherman's Friend, Nin jiom, Comvita, Vocalzone, Good Health, KANRO CO., LTD., UHA Mikakuto, Zirkulin, among others. In 2025, the global top five players held approximately % of revenue, underscoring a moderately concentrated competitive landscape. We have surveyed manufacturers, suppliers, distributors, and industry experts, gathering insights on sales trends, price dynamics, product type shifts, recent development plans, and potential risks. The report aims to provide a comprehensive presentation of the market, combining quantitative and qualitative analysis to help readers develop growth strategies, assess competitive positioning, and make informed decisions. It contains market size and forecasts for revenue and volume, segment breakdowns by product type (Candy vs. Lozenges) and application (Supermarket vs. Drugstore), and regional analyses covering North America, Europe, Asia, South America, and the Middle East & Africa.
North America continues to hold the dominant position in the global sore throat lozenges and candy market. In 2025 the United States alone contributed roughly USD 1.3 billion, driven by strong consumer spending power, high retail density, and the prevalence of seasonal respiratory infections. Canadian and Mexican markets add another USD 250 million collectively, supported by well‑established pharmacy chains and growing demand for natural‑ingredient lozenges. The region benefits from a mature OTC (over‑the‑counter) distribution network, aggressive marketing by legacy brands such as Ricola and Fisherman's Friend, and a steady shift toward sugar‑free, herbal formulations that appeal to health‑conscious consumers.
Key Highlights:
Asia‑Pacific is forecast to become the fastest‑growing region, with a compound annual growth rate of approximately 6.2 % through 2034. China’s market is expected to reach USD 1.1 billion by 2034, while India’s rapidly expanding middle class is projected to push its market size beyond USD 500 million. Urbanization, rising disposable incomes, and a cultural preference for honey‑based and herbal lozenges are key drivers. Moreover, the surge in online grocery penetration across Southeast Asian economies accelerates product accessibility, especially for younger consumers who favor flavored candy lozenges.
Key Highlights:
Seasonal spikes in colds and flu remain the primary catalyst for demand surges worldwide. In North America, sales typically rise 18 % during the winter months, whereas in Asia‑Pacific the increase can exceed 25 % due to higher humidity‑driven throat irritation. Retailers respond by expanding shelf space for “cold‑season” bundles that combine lozenges with vitamin C tablets. In Europe, the rise of teleworking has led to increased indoor air dryness, prompting a modest but steady demand for soothing candy lozenges year‑round. Middle East markets see a pronounced demand during the hot, dusty summer months, where menthol‑infused products are favored for their cooling sensation.
Key Highlights:
Beyond the United States and China, several countries are emerging as hotbeds for lozenge and candy innovation. Germany’s robust nutraceutical sector is fostering collaborations between confectionery firms and biotech startups to develop probiotic‑infused lozenges. South Korea is pioneering “smart” lozenges that incorporate micro‑encapsulated vitamin D, targeting post‑pandemic immunity concerns. Brazil’s growing natural‑product market is encouraging local producers to experiment with Amazonian honey and guarana extracts, creating distinctive flavors that appeal to both domestic and export markets.
Retail channel diversification is reshaping consumption patterns across all regions. In North America, major pharmacy chains have integrated click‑and‑collect services, boosting “instant‑heal” lozenge sales by 9 % in 2023. Europe’s hyper‑markets are dedicating larger “wellness aisles” to sugar‑free, herbal lozenges, reflecting a 7 % growth in that segment. In Asia‑Pacific, mobile commerce platforms such as Alibaba’s Tmall and India’s BigBasket now allocate dedicated health corridors, driving a 15 % rise in online lozenge purchases. South America’s rapid rollout of supermarket‑to‑door delivery services in Brazil and Argentina has similarly accelerated market reach, especially in remote areas where traditional pharmacies are scarce.
Key Highlights:
Europe holds a substantial share of the global market, accounting for roughly 28 % of worldwide revenue in 2025. The United Kingdom, Germany, and France together contribute more than half of Europe’s total sales, driven by high consumer awareness of natural‑herbal remedies and strong regulatory frameworks that promote clear health claims on packaging. The region’s mature retail environment, with extensive pharmacy chains and specialty health stores, supports consistent demand for both traditional honey‑lemon lozenges and newer functional candy formulations.
Key Highlights:
The Middle East & Africa region is set to register the highest growth rate, with a projected CAGR of 7.1 % through 2034. Saudi Arabia and the United Arab Emirates are leading the surge, each expected to exceed USD 150 million in sales by the end of the forecast period. Rapid urbanization, rising disposable incomes, and an increasing preference for convenient OTC solutions to alleviate throat irritation caused by desert dust and air‑conditioning are primary growth catalysts.
Key Highlights:
In the Middle East, hot, dry climates intensify throat dryness, prompting a pronounced demand for menthol‑infused lozenges during summer months. Conversely, cooler winter periods see a spike in honey‑lemon and ginger‑based products as consumers seek soothing relief from viral infections. In Africa, the prevalence of seasonal flu outbreaks in Sub‑Saharan regions drives periodic surges in lozenge purchases, often coinciding with school calendars and public health vaccination drives.
Key Highlights:
Saudi Arabia and the United Arab Emirates are emerging as leading innovation hubs, with substantial investments in nutraceutical research and local manufacturing capabilities. Both countries are fostering public‑private partnerships to develop lozenges enriched with traditional Middle Eastern ingredients such as black seed oil and frankincense, positioning themselves as exporters of premium functional candy to neighboring markets.
The proliferation of modern trade outlets, such as large‑format supermarkets and dedicated health‑care pharmacies, is expanding product accessibility across the Middle East & Africa. In 2024, Saudi Arabia saw a 12 % increase in OTC aisle space dedicated to throat lozenges, while Amazon ME launched a specialized health‑care storefront that boosted online sales by 18 % year‑over‑year. These retail developments are complemented by aggressive private‑label strategies, offering cost‑effective alternatives that resonate with price‑sensitive consumers.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include Ryukakusan Co., Ltd., Ricola, Fisherman's Friend, Nin Jiom, Comvita, Vocalzone, Good Health, KANRO CO., LTD., UHA Mikakuto, Zirkulin, among others.
-> Key growth drivers include rising incidence of upper‑respiratory infections, growing consumer preference for natural and functional confectionery, and expanding over‑the‑counter self‑care market.
-> North America holds the largest share, while Asia‑Pacific is the fastest‑growing region, driven by strong demand in China and India.
-> Emerging trends include bio‑based and sugar‑free formulations, premium herbal blends, and digital direct‑to‑consumer distribution channels.
